← SynDRA
IPRAGLIFLOZIN
SynDRA canonical compound SYN0029035 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | SLC5A2 |
|---|
| Mechanism of action | sodium/glucose cotransporter inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- SLC5A2
- SLC5A1
- Slc5a1
- Slc5a2
Mechanisms of action (all sources)
- SLC5A2 INHIBITOR
- Sodium/glucose cotransporter 2 inhibitor
- SLC5A1 INHIBITOR
- sodium/glucose cotransporter inhibitor
- SLC5A2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLC6A3
- ABL1
- PDE3A
- HRH3
- HTR1A
- HTR2B
- MAOA
- MAPK1
- OPRM1
- PDE4A
- GSK3B
- PGR
- PTGS1
- SLC6A2
- SLC6A4
- TBXA2R
- HDAC6
- FGFR2
- ACHE
- BRPF1
- ADORA3
- ADRA1A
- ADRA2A
- AR
- AURKA
- BRD4
- CDK2
- F2
- CHRM1
- CHRM2
- CSNK1D
- DRD1
- DRD3
- ESR1
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- suglat
- ipragliflozin L-proline
- ASP1941
- Ipragliflozine
- Ipragliflozina
- ASP-1941
- Ipragliflozin L-proline
- UNII-M6N3GK48A4
- Suglat (TN)
- Ipragliflozin (L-Proline)
- M6N3GK48A4
- Ipragliflozin L-proline [JAN]
- Ipragliflozin L-proline (JAN)
- Ipragliflozin mixture with proline
- DTXSID20241771
- EX-A2771
- L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1)
- HY-14894A
- AKOS027321043
- L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1)
- AK310367
- DS-11639
- AC-29892
- CS-0019749
- D10200
- BRD-K51247865
- ipragliflozin-l-proline
- ASP 1941
- ipragliflozina
- ipragliflozine
- 3N2N8OOR7X
- ipragliflozinum
- RefChem:148654
- A10BK05
- DTXCID401517751
- Ipragliflozin [INN]
- MFCD19443744
- Ipragliflozin (ASP1941)
Look up IPRAGLIFLOZIN in the interactive SynDRA portal →